FDA-Approved Oligonucleotide Therapies in 2017
Cy A. Stein,Daniela Castanotto +1 more
Reads0
Chats0
TLDR
Of all the molecules evaluated as of January 2017, the regulatory authorities assessed that six provided clear clinical benefit in rigorously controlled trials and the story of these six is given in this review.About:
This article is published in Molecular Therapy.The article was published on 2017-05-03 and is currently open access. It has received 508 citations till now. The article focuses on the topics: Clinical trial.read more
Citations
More filters
Journal ArticleDOI
Block Copolymer Micelles in Nanomedicine Applications.
TL;DR: By shaping these features, polymeric micelles have been propitious for delivering a wide range of therapeutics through effective sensing of targets in the body and adjustment of their properties in response to particular stimuli, modulating the activity of the loaded drugs at the targeted sites, even at the subcellular level.
Journal ArticleDOI
Noncoding RNA therapeutics - challenges and potential solutions.
TL;DR: In this article, the authors discuss key challenges facing ncRNA therapeutics, including issues associated with specificity, delivery and tolerability, and focus on promising emerging approaches that aim to boost their success.
Journal ArticleDOI
An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites.
Mohamed F. Attia,Mohamed F. Attia,Nicolas Anton,Justine Wallyn,Ziad Omran,Thierry F. Vandamme +5 more
TL;DR: These properties describing the convenient choice between passive and active targeting mechanisms with details are discussed, illustrated with examples of targeting agents up to preclinical research or clinical advances.
Journal ArticleDOI
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Xiulong Shen,David R. Corey +1 more
TL;DR: The chemical modifications and molecular mechanisms that make synthetic nucleic acid drugs possible and lessons learned from recent clinical trials will be summarized.
Journal ArticleDOI
Therapeutic Targeting of Long Non-Coding RNAs in Cancer.
TL;DR: Examples of lncRNAs that demonstrate the diversity of their function in various cancer types are discussed and recent advances in nucleic acid drug development with a focus on oligonucleotide-based therapies as a novel approach to inhibit tumor progression are discussed.
References
More filters
Journal ArticleDOI
Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase
Craig Tuerk,Larry Gold +1 more
TL;DR: High-affinity nucleic acid ligands for a protein were isolated by a procedure that depends on alternate cycles of ligand selection from pools of variant sequences and amplification of the bound species.
Journal ArticleDOI
Pegaptanib for Neovascular Age-Related Macular Degeneration
TL;DR: Pegaptanib, an anti-vascular endothelial growth factor therapy, was evaluated in the treatment of neovascular age-related macular degeneration.
Journal ArticleDOI
Fibroblast growth factors, their receptors and signaling.
TL;DR: FGF signaling also appears to play a role in tumor growth and angiogenesis, and autocrine FGF signaling may be particularly important in the progression of steroid hormone-dependent cancers to a hormone-independent state.
Journal ArticleDOI
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
Eugene W. M. Ng,David T. Shima,Perry Calias,Emmett T. Cunningham,David R. Guyer,Anthony P. Adamis +5 more
TL;DR: Pegaptanib was shown in clinical trials to be effective in treating choroidal neovascularization associated with age-related macular degeneration and has the notable distinction of being the first aptamer therapeutic approved for use in humans, paving the way for future aptamer applications.
Book ChapterDOI
The FGF family of growth factors and oncogenes.
TL;DR: The FGF family includes seven members that share a varying degree of homology at the protein level and appear to have a similar broad mitogenic spectrum and promote the proliferation of a variety of cells of mesodermal and neuroectodermal origin.
Related Papers (5)
Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide
RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
C. Frank Bennett,Eric E. Swayze +1 more
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
David Adams,Alejandra González-Duarte,William O'Riordan,Chih-Chao Yang,Mitsuharu Ueda,Arnt V. Kristen,Ivailo Tournev,Hartmut Schmidt,Teresa Coelho,John L. Berk,Kon Ping Lin,Giuseppe Vita,Shahram Attarian,Violaine Planté-Bordeneuve,Michelle M. Mezei,Josep M. Campistol,Juan Buades,Thomas H. Brannagan,Byoung Joon Kim,Jeeyoung Oh,Yesim Parman,Yoshiki Sekijima,Philip N. Hawkins,Scott D. Solomon,Michael Polydefkis,Peter J. Dyck,Pritesh Gandhi,Sunita Goyal,Jihong Chen,Andrew Strahs,Saraswathy V. Nochur,Marianne T. Sweetser,Pushkal Garg,Pushkal Garg,Akshay Vaishnaw,Akshay Vaishnaw,Jared Gollob,Ole B. Suhr +37 more